KEY POINTS

Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company’s patents, and is seeking to recover damages.

The move escalates the feud between Novo and Hims, which said on Saturday it will stop offering its newly launched obesity pill copycat after facing scrutiny from federal regulators and legal threats from the Danish drugmaker.

Novo estimated in January that as many as 1.5 million Americans are using compounded GLP-1 drugs.